InterMune has presented the results of pooled analyses of data from three Phase III trials (ASCEND [Study 016] and CAPACITY...
Xadago is indicated for the treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.